FDA asks Citius for en­hanced prod­uct test­ing in CRL for non-Hodgkin lym­phoma drug Lym­phir

The FDA hit Citius Phar­ma­ceu­ti­cals with a com­plete re­sponse let­ter (CRL) for its treat­ment of re­lapsed or re­frac­to­ry cu­ta­neous T-cell lym­phoma (CT­CL), a rare form of non-Hodgkin lym­phoma.

The agency wants to see “en­hanced prod­uct test­ing” and “ad­di­tion­al con­trols” that the com­pa­ny agreed to with the FDA dur­ing the mar­ket ap­pli­ca­tion re­view of de­nileukin difti­tox, mar­ket­ed as Lym­phir. Citius not­ed the CRL had noth­ing to do with safe­ty, ef­fi­ca­cy or the pre­scrib­ing in­for­ma­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER